论文部分内容阅读
目的:探讨弥漫大B细胞淋巴瘤（DLBCL）患者的预后及其影响因素。方法:回顾性分析山西省肿瘤医院2013年1月至2017年6月收治的355例DLBCL患者的临床资料，探讨患者临床特征与预后的关系，采用log-rank检验进行单因素分析，Cox回归模型进行多因素分析。结果:355例患者中男性183例，女性177例，中位年龄59岁（5～85岁）。1年生存率为87.0%，2年生存率为69.5%，3年生存率为61.1%。多因素分析显示，年龄≥60岁（n χ2=11.020，n P=0.001）、临床分期晚（n χ2=13.005，n P<0.01）、Karnofsky评分<80分（n χ2=8.722，n P=0.003）、乳酸脱氢酶（LDH）升高（n χ2=10.946，n P=0.001）、βn 2微球蛋白（βn 2-MG）升高（n χ2=5.918，n P=0.015）、吸烟（n χ2=6.981，n P=0.008）是DLBCL患者预后的危险因素；行肿瘤切除术（n χ2=3.842，n P=0.050）、使用利妥昔单抗（n χ2=8.041，n P=0.005）是DLBCL患者预后的保护因素。n 结论:DLBCL患者中，年龄≥60岁、临床分期晚、Karnofsky评分低、LDH升高、βn 2-MG升高、吸烟的患者预后差，行肿瘤切除术和使用利妥昔单抗患者预后较好，患者应定期复查，尤其应该检查上述相关危险因素。n “,”Objective:To explore the prognosis and influencing factors of diffuse large B-cell lymphoma (DLBCL).Methods:The clinical data of 355 patients with DLBCL in Shanxi Provincial Cancer Hospital from January 2013 to June 2017 were retrospectively analyzed. The relationship between clinical characteristics and prognosis of the patients was explored. The log-rank test was used for univariate analysis, and Cox regression model was used for multivariate analysis.Results:Among the 355 patients, there were 183 males and 177 females, with a median age of 59 years old (5-85 years old). The 1-year survival rate was 87.0%, 2-year survival rate was 69.5%, and 3-year survival rate was 61.1%. Multivariate analysis showed that age ≥60 years old (n χ2 = 11.020, n P = 0.001), late clinical staging (n χ2 = 13.005, n P < 0.01), Karnofsky scores < 80 scores ( n χ2 = 8.722, n P = 0.003), increased lactate dehydrogenase (LDH) (n χ2 = 10.946, n P = 0.001), increased β n 2 microglobulin (βn 2-MG) (n χ2 = 5.918, n P = 0.015), smoking (n χ2 = 6.981, n P = 0.008) were prognostic risk factors for patients with DLBCL. Tumor resection (n χ2 = 3.842, n P = 0.050) and rituximab (n χ2 = 8.041, n P = 0.005) were protective prognostic factors for patients with DLBCL.n Conclusions:DLBCL patients with age ≥60 years old, late clinical staging, lower Karnofsky score, increased LDH, increased β n 2-MG and smoking have a poor prognosis. Patients who underwent tumor resection and rituximab have a better prognosis. Patients with DLBCL should be reviewed regularly, especially for the risk factors mentioned above.n